BioAge Labs (BIOA) Common Equity (2023 - 2026)

BioAge Labs (BIOA) has 4 years of Common Equity data on file, last reported at $379.1 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 21.06% year-over-year to $379.1 million; the trailing twelve-month figure through Mar 2026 stood at $379.1 million (up 21.06% YoY), and the FY2025 full-year result was $272.1 million, down 15.81% from the prior year.
• Common Equity grew to $379.1 million in Q1 2026, from $272.1 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $379.1 million in Q1 2026 to a low of -$197.1 million in Q2 2024.
• A 4-year average of $133.1 million and a median of $277.5 million in 2025 frame the typical range for Common Equity.
• Across the five-year window, Common Equity jumped 304.88% in 2024 and retreated 15.81% in 2025, its largest moves.
• Tracing BIOA's Common Equity over 4 years: stood at -$173.4 million in 2023, then surged by 286.35% to $323.1 million in 2024, then retreated by 15.81% to $272.1 million in 2025, then surged by 39.36% to $379.1 million in 2026.
• Business Quant data shows BIOA's Common Equity at $379.1 million in Q1 2026, $272.1 million in Q4 2025, and $277.5 million in Q3 2025.